Collaborations & Alliances

Amgen, Arrowhead Ink Two Cardiovascular Agreements

Aims to develop and commercialize therapies using Arrowhead's subcutaneous RNAi delivery platform

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen and Arrowhead Pharmaceuticals have entered two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These programs use Arrowhead’s subcutaneous RNAi delivery platform designed to target and shut down specific gene products that contribute to various diseases. Under one agreement, Amgen receives a worldwide, exclusive license to Arrowhead’s RNAi ARC-LPA program, and under the second agreement, Amgen re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters